Trends in hepatitis C virus seroprevalence and associated risk factors among men who have sex with men in Montréal: results from three cross-sectional studies (2005, 2009, 2018)

Charlotte Lanièce Delaunay,1,2 Joseph Cox,2,3 Marina Klein,1,2 Gilles Lambert,3,4 Daniel Grace,5 Nathan John Lachowsky ●,6 Mathieu Maheu-Giroux ●1

ABSTRACT

Objectives To eliminate the hepatitis C virus (HCV) by 2030, Canada must adopt a microelimination approach targeting priority populations, including gay, bisexual and other men who have sex with men (MSM). Accurately describing HCV prevalence and risk factors locally is essential to design appropriate prevention and treatment interventions. We aimed to estimate temporal trends in HCV seroprevalence between 2005 and 2018 among Montréal MSM, and to identify socioeconomic, behavioural and biological factors associated with HCV exposure among this population.

Methods We used data from three cross-sectional surveys conducted among Montréal MSM in 2005 (n=1795), 2009 (n=1258) and 2018 (n=1086). To ensure comparability of seroprevalence estimates across time, we standardised the 2005 and 2009 time-location samples to the 2018 respondent-driven sample. Time trends overall and stratified by HIV status, history of injection drug use (IDU) and age were examined. Modified Poisson regression analyses with generalised estimating equations were used to identify factors associated with HCV seropositivity pooling all surveys.

Results Standardised HCV seroprevalence among all MSM remained stable from 7% (95% CI 3% to 10%) in 2005, to 8% (95% CI 1% to 9%) in 2009 and 8% (95% CI 4% to 11%) in 2018. This apparent stability hides diverging temporal trends in seroprevalence between age groups, with a decrease among MSM <30 years old and an increase among MSM aged ≥45 years old. Lifetime IDU was the strongest predictor of HCV seropositivity, and no association was found between HCV seropositivity and sexual risk factors studied (condomless anal sex with men of serodiscordant/unknown HIV status, number of sexual partners, group sex).

Conclusions HCV seroprevalence remained stable among Montréal MSM between 2005 and 2018. Unlike other settings where HCV infection was strongly associated with sexual risk factors among MSM, IDU was the pre-eminent risk factor for HCV seropositivity. Understanding the intersection of IDU contexts, practices and populations is essential to prevent HCV transmission among MSM.

INTRODUCTION

Canada is not on track to eliminate the hepatitis C virus (HCV) as a public health threat by 2030.1,2 Gay, bisexual and other men who have sex with men (MSM) have been identified as a priority population for HCV microelimination.3–5 Since 2000, HCV epidemics have been reported among MSM living with HIV in industrialised countries.6 In this population, global HCV incidence has increased from 2.6 per 1000 person-years pre-2000 to 8.1 per 1000 person-years post-2010,6 with high re-infection rates,6 and global HCV seroprevalence was estimated at 6.4% from 2002 to 2015.3 Comparatively, the HCV burden has remained stable among HIV-negative MSM, with estimates of seroprevalence ranging from 0.0% to 3.4%8–13 and a global incidence of 0.4 per 1000 person-years.14 Nevertheless, acute HCV infections have recently been reported among HIV-negative MSM without a history of injection drug use (IDU) in Europe,15 the USA16 and Vancouver, British Columbia (Canada).17 These data may mask variations across geographical settings, highlighting the importance of local contexts and related risks.

In industrialised countries, most HCV infections have been attributed to the use of unsterile needles and drug paraphernalia, and receipt of blood or blood products before the introduction of HCV screening.18 In parallel, evidence from Europe, the USA and Vancouver shows that sexual transmission can account for a substantial proportion of incident HCV infections among MSM.6 17 19–21 Two other overlapping population groups may be at increased risk of being chronically infected with HCV: individuals born between 1945 and 1975, due to exposures to HCV-contaminated blood and blood products before 1990,25 and immigrants originating from HCV endemic countries.23 Socioeconomic factors such as education and income can also influence the risk of acquiring HCV among MSM.19 24–26 The impact of these factors on HCV transmission among MSM subgroups is context-dependent and may vary by HIV status. Additionally, sexual and injecting behaviours may interact, for example through the practice of chemsex, a form of sexualised drug use associated with a higher risk of HCV infection among MSM.27 28 To date, there has been little evidence of sexual transmission of HCV among MSM in Canada.29 13 17 29 30
The variability in HCV incidence and prevalence among MSM populations, as well as the diversity of potential routes of transmission reflect the importance of using locally valid epidemiological evidence to inform tailored interventions targeting microelimination. Scarce evidence exists on HCV prevalence and risk factors among MSM subgroups in Canadian cities. In Vancouver, HCV seroprevalence among all MSM was estimated at 5% in a cross-sectional study conducted in 2008–2009. 12 In this city, 17% of MSM living with HIV tested HCV seropositive, against 10% in a similar study conducted in Toronto, Ontario in 2010–2012. 13 Temporal trends in HCV seroprevalence among MSM have not been assessed in Canada, and available cross-sectional data suggest potential within-country variability in seroprevalence. In Montréal, Québec (Canada), up-to-date and comprehensive information is required to inform HCV elimination interventions among MSM.

In this study, we aimed to (1) investigate temporal trends in HCV seroprevalence among MSM living in Montréal from 2005 to 2018, overall and stratified by HIV status, IDU status and age group; and (2) identify the social, behavioural and biological factors associated with HCV exposure among this heterogeneous population.

METHODS

Data sources and harmonisation
Three cross-sectional surveys of sexually transmitted and blood-borne infections were conducted among Montréal MSM in 2005, 2009 and 2018: Engage cohort study, respectively. These surveys have been previously described. [w1,w2] Briefly, they combined HIV, HCV and syphilis surveillance and behavioural monitoring through self-administered questionnaires. In 2005 (n=1957) and 2009 (n=1873), locations where MSM can be found were identified. In 2005, venues were selected using convenience sampling, and in 2009 time-location sampling was used, where sampling probabilities are generated at the location and individual level. [w3,w4] In 2018, a community-based sample of 1179 MSM were recruited using respondent-driven sampling (RDS), a link-tracing method that uses information about participants’ social networks to estimate their probability of being recruited and adjust for the biases associated with oversampling/undersampling of certain groups. [w5] Eligibility criteria varied slightly across the three surveys (online supplementary file 2).

To compare the three surveys, we first harmonised the eligibility criteria across data sets. Our analyses were restricted to cisgender men aged ≥18 years who reported sexual activity with a man in the past 6 months (P6M) and resided in Montréal. The sensitivity and specificity of the assays used for anti-HCV antibody detection in the three surveys were comparable (sensitivity: 100% in 2005, 2009 and 2018; specificity: 99.95% in 2005 and 2009, and 99.69% in 2018). [w1,w2,w6]

Temporal trends in HCV seroprevalence
We estimated HCV seroprevalence in 2005, 2009 and 2018, among all MSM, stratified by HIV status, lifetime history of IDU and age group, and among HIV-negative MSM without a history of IDU. To ensure comparability of the samples across time, regression-based standardisation was performed. The RDS-weighted 2018 survey was used as the standard and the other surveys were adjusted to yield the same distribution of age, sexual orientation, annual income and first language. This was achieved by first fitting multivariable logistic regression models with HCV seropositivity as the outcome (defined as a positive anti-HCV antibody test) to the 2005 and 2009 data, separately. Age was modelled using a restricted cubic spline, [w7] and we investigated the presence of multiplicative statistical interaction between each pair of covariates. For the stratified analyses, the same model was fitted separately among each subgroup of interest. Using these models, we then predicted the individual probability of testing HCV seropositive using the covariate patterns observed in the 2018 standard sample, among all MSM and by subgroup. Finally, we computed the weighted mean of these individual probabilities using Volz-Heckathorn weights [w8] to estimate standardised HCV seroprevalence among the different groups at all time points. We obtained 95% CIs using cluster-level block bootstrap, with clusters corresponding to the recruitment site in 2005 (n=40 sites) and 2009 (n=39 sites) and to the initial seed of the recruitment chain in 2018 (n=27 seeds). We performed complete case analyses as only 5% of observations had any missing value for the variables used in these estimations. [w9]

Factors associated with HCV seropositivity
Pooling data from the three surveys, we examined potential determinants of HCV seropositivity using prevalence ratios. We used univariable and multivariable modified Poisson regression models with generalised estimating equations (with exchangeable correlation structures), accounting for clustering. [w10–w12] The following predictors were selected a priori based on their potential association with HCV: survey year, lifetime history of IDU, HIV seropositivity, history of syphilis (defined as a reactive serological test), age (categorical), birth outside of Canada, annual income ≥$C30,000, education level higher than high school, sexual orientation other than gay/homosexual, self-identification as Indigenous, first language other than French/English, and specific sexual practices reported in the P6M: transactional sex (defined as having given/received money, drugs, or other goods or services in exchange for sex), condomless anal sex (CAS) with a man of serodiscordant/unknown HIV status, >5 male sexual partners and group sex. We used multiple imputation by chained equations for missing values as 33% of observations had at least one missing value for these variables, principally information regarding CAS (23%), [w13,w14] and history of IDU (17%). 

We also investigated whether the impact of sexual practices on HCV varied by HIV status, and quantified the joint association of lifetime IDU and sexual behaviours with the outcome. We assessed the presence of additive and multiplicative interactions between the following terms: (1) HIV seropositivity and four sexual risk factors reported in the P6M (ie, transactional sex, CAS with a man of serodiscordant/unknown HIV status, number of sexual partners and group sex); and (2) history of IDU and the same four factors. To evaluate multiplicative interaction, we included the product term of each selected pair of factors in the main analysis model separately and examined the estimate and CI of each product term coefficient. [w15] Additive interaction was assessed by obtaining the relative excess risk due to interaction and its CI. [w16,w17] All analyses were conducted using R V.3.5.3, [w18] with the RDX, [w19] geepack, [w20] mice, [w21] and dplyr [w21] packages.

Written informed consent was obtained from all participants.

RESULTS

Characteristics of participants (prestandardisation)
A total of 4139 MSM were included in our analyses (1795 in 2005; 1258 in 2009; 1086 in 2018) (figure 1). The pre-standardised proportion of participants living with HIV was 13% (95% CI 11% to 14%) in 2005, 15% (95% CI 13% to
Epidemiology

Temporal trends in HCV seroprevalence (poststandardisation)
Standardised HCV seroprevalence among all MSM remained stable, ranging from 7% (95% CI 3% to 10%) in 2005, to 8% (95% CI 1% to 9%) in 2009 and 8% (95% CI 4% to 11%) in 2018 (figure 2, online supplementary file 3).

Stratification by HIV and IDU status did not reveal consistent temporal trends in HCV seroprevalence among these subgroups. We observed a drop in estimates for MSM living with HIV and MSM with a history of IDU in 2009 and obtained relatively wide CIs among these two groups due to smaller numbers of observations. The highest HCV seroprevalence point estimates were obtained among participants with a history of IDU, with 74% (95% CI 62% to 85%) in 2005, 37% (95% CI 8% to 48%) in 2009 and 60% (95% CI 42% to 77%) in 2018. In contrast, HCV seroprevalence among MSM without a history of IDU was 3% (95% CI 1% to 4%) in 2005, 2% (95% CI 0% to 3%) in 2009 and 2% (95% CI 0% to 4%) in 2018. HCV seropositivity was also far more common among MSM living with HIV at 17% (95% CI 6% to 25%) in 2005, 8% (95% CI 2% to 16%) in 2009 and 17% (95% CI 6% to 29%) in 2018, than among HIV-negative MSM at 6% (95% CI 3% to 8%) in 2005, 8% (95% CI 0% to 9%) in 2009 and 6% (95% CI 3% to 9%) in 2018. Finally, HCV seroprevalence remained relatively stable among HIV-negative MSM without a history of IDU at 2% (95% CI 1% to 3%) in 2005, 2% (95% CI 0% to 4%) in 2009 and 1% (95% CI 0% to 2%) in 2018.

Factors associated with HCV seropositivity
Lifetime history of IDU was the strongest predictor of HCV seropositivity in our population (table 2). Increased age, recent transactional sex, HIV seropositivity and sexual orientation other than gay/homosexual were also associated with increased HCV seroprevalence. Our results suggest an association between socioeconomic factors and the outcome: MSM with higher income and education level were less likely to test HCV-seropositive. Being born outside of Canada was also associated with lower HCV seroprevalence. Few participants identified as Indigenous (1%–2% across surveys), leading to wide uncertainty around the adjusted prevalence ratio for this population group. We found no association between the recent sexual behaviours examined and HCV seropositivity. Finally, first language other than French/English was not associated with variation in the outcome.

Sensitivity analyses
We detected negative additive and multiplicative interactions between HIV seropositivity and transactional sex in the P6M (online supplementary file 4). The presence of negative additive and multiplicative interactions means that the association with HCV seropositivity when both factors are present is smaller than, respectively, the sum and product of the individual associations of the two factors with the outcome. We also identified
negative additive interactions between history of IDU and each sexual risk factor studied, separately, and a positive multiplicative interaction between history of IDU and group sex in the P6M. A positive multiplicative interaction indicates that the association when both factors are present is stronger than the product of the individual associations.

**DISCUSSION**

Standardising and pooling three large cross-sectional surveys of MSM from 2005 to 2018, our results suggest that HCV seroprevalence has remained stable around 8% in Montréal, at a higher level than in other North American settings (3%–5%).

Despite this overall stability, we observed diverging trends among MSM from 2005 to 2018, our results suggest that HCV seroprevalence among MSM without a history of IDU (2%–3%) was also twice as high as that estimated in Vancouver for the same group. These numbers are greater than the 1% HCV seroprevalence estimated for the general Canadian population. Yet, the seroprevalence observed among HIV-negative MSM in Montréal ranged from 6% to 8% between 2005 and 2018, on the high end of estimates from Canada, the USA and Europe.

The seroprevalence estimated among MSM without a history of IDU (2%–3%) was also twice as high as that estimated in Vancouver for the same group. These numbers are greater than the 1% HCV seroprevalence estimated for the general Canadian population. Yet, the seroprevalence observed among HIV-negative MSM in Montréal ranged from 6% to 8% between 2005 and 2018, on the high end of estimates from Canada, the USA and Europe. The seroprevalence estimated among MSM without a history of IDU (2%–3%) was also twice as high as that estimated in Vancouver for the same group. These numbers are greater than the 1% HCV seroprevalence estimated for the general Canadian population.

**Table 1** Description of participants included in three cross-sectional biobehavioural surveys of men who have sex with men conducted in Montréal, Québec (Canada) (2005–2018, before any imputation or standardisation)

| Characteristics | 2005 (n=1795) | 2009 (n=1258) | 2018 (n=1086) |
|-----------------|--------------|--------------|--------------|
| HCV seropositivity | 95 (5)       | 49 (4)       | 58 (5)       |
| HIV seropositivity | 224 (13)     | 193 (15)     | 200 (18)     |
| Reactive syphilis serology | 93 (5)     | 116 (9)      | 194 (18)     |
| Age (years) | 38 (28–47)* | 40 (30–47)* | 34 (28–49)* |
| Income ≥$30,000 in the past year | 891 (50) | 763 (61) | 461 (42) |
| Education level higher than high school | 1217 (68) | 537 (43) | 806 (74) |
| Sexual orientation other than gay/homosexual | 336 (19) | 107 (9) | 205 (19) |
| Born outside of Canada | 244 (14) | 194 (15) | 348 (32) |
| Self-reported ethnicity or family background | | | |
| Indigenous | 33 (2)† | 16 (1) | 9 (1) |
| English Canadian | 146 (8)† | 108 (9) | 103 (9) |
| French Canadian | 1219 (68)† | 865 (69) | 537 (49) |
| European | 105 (6)† | 119 (9) | 157 (14) |
| Asian | 31 (2)† | 14 (1) | 40 (4) |
| Arab or North African | 28 (2)† | 20 (2) | 44 (4) |
| Sub-Saharan African | 3 (<1)† | 3 (<1) | 9 (1) |
| Latin, South or Central American | 60 (3)† | 29 (2) | 92 (8) |
| Caribbean | 20 (1)† | 7 (1) | 9 (1) |
| Oceanian (eg, Australian, Pacific Islander) | 2 (<1)† | 0 | 1 (<1) |
| Other | 84 (5)† | 61 (5) | 74 (7) |
| First language other than French/English | 125 (7) | 101 (8) | 74 (7) |
| Transactional sex in the P6M | 329 (18)† | 187 (15)† | 108 (10) |
| CAS with a man of serodiscordant/unknown HIV status in the P6M | 200 (11)† | 251 (20)† | 395 (36)† |
| >5 male sexual partners in the P6M§ | 664 (37) | 569 (45) | 533 (51) |
| Group sex in the P6M | 479 (27) | 407 (32) | 252 (23) |
| History of injection drug use¶ | 128 (7)† | 147 (12) | 110 (10) |

*Median (IQR).
†More than 2% of observations were missing for this variable, in this data set.
‡Transactional sex was defined as having given/received money, drugs, or other goods or services in exchange for sex in the P6M.
§Male sexual partners included both oral and anal sexual partners.
¶Lifetime injection of any non-prescribed drug was considered as a previous experience of injection drug use.
CAS, condomless anal sex; HCV, hepatitis C virus; P6M, past 6 months.

HCV seroprevalence was particularly high among MSM living with HIV and those with a history of IDU. The drop in seroprevalence observed in 2009 among these groups could indicate temporal changes in injecting behaviours (eg, increased number of new injectors never exposed to HCV). However, these results could reflect remaining differences in the composition of the samples post-standardisation. HCV seroprevalence among HIV-negative MSM in Montréal ranged from 6% to 8% between 2005 and 2018, on the high end of estimates from Canada, the USA and Europe. The seroprevalence estimated among MSM without a history of IDU (2%–3%) was also twice as high as that estimated in Vancouver for the same group. These numbers are greater than the 1% HCV seroprevalence estimated for the general Canadian population. Yet, the seroprevalence observed among HIV-negative MSM without a history of IDU (1%–2%) was comparable with that among the general population, in line with previous findings from Argus 1. Yet, the relatively high HCV seroprevalence observed among all MSM may therefore reflect frequent exposure to the virus among subgroups with particular vulnerabilities (eg, HIV infection) or risk behaviours (eg, IDU).

Reporting a history of IDU was the strongest predictor of HCV seropositivity among Montréal MSM between 2005 and
2018. This is concerning given that the proportion of MSM who reported lifetime IDU in Engage (6.9% [w2]) is 12 times that reported among the general population in Montréal (0.5% [w26]). Aside from recent transactional sex, which encompasses having given/received drugs in exchange for sex, we observed no association between sexual behaviours and HCV seroprevalence. These results are consistent with those obtained in Toronto [13] and a study conducted in 2001 among Montréal MSM. [29] However, they contrast with emerging evidence from Vancouver [17] and with studies conducted in Europe [6] and the USA [14] where sexual risk factors were strongly associated with new HCV infections among MSM.

We observed no positive interactions between HIV positivity and sexual behaviours. One potentially important risk factor that we could not directly investigate is chemsex. Nevertheless, the positive multiplicative interaction observed between group sex...
and IDU could partly capture the association of chemsex practices with HCV seroprevalence, although we could not measure the concomitance of injecting and sexual behaviours. No positive interaction was observed between history of IDU and other sexual risk factors.

Altogether, higher socioeconomic status (ie, income and education) was associated with lower HCV seroprevalence. Our data did not allow us to specifically examine the relationship between birth in HCV endemic countries and HCV seropositivity. In this regard, interpreting the negative association between birth outside of Canada and HCV seroprevalence is challenging. Having a first language other than French/English, another proxy for country of origin, was not associated with the outcome. Reporting a sexual orientation other than gay/homosexual was positively associated with HCV seropositivity. Because data on sexual orientation were categorised differently across our three surveys, the ‘other’ category represents varied homosexual was positively associated with HCV seropositivity. The outcome. Reporting a sexual orientation other than gay/homosexual was positively associated with HCV seropositivity. Unlike other settings where HCV infection was strongly associated with sexual risk factors among MSM subgroups, history of IDU was the pre-eminent risk factor for HCV seropositivity among MSM living in Montréal. Understanding the intersection of IDU contexts, practices and populations is essential to prevent HCV transmission among these overlapping populations.

**CONCLUSIONS**

HCV seroprevalence remained high among Montréal MSM between 2005 and 2018, likely reflecting frequent exposure to the virus among MSM living with HIV and MSM with a history of IDU. Unlike other settings where HCV infection was strongly associated with sexual risk factors among MSM subgroups, history of IDU was the pre-eminent risk factor for HCV seropositivity among Montréal MSM. Understanding the intersection of IDU contexts, practices and populations is essential to prevent HCV transmission among these overlapping populations.

**Author affiliations**

1. Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montréal, Québec, Canada
2. Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada
3. Direction régionale de santé publique, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l’Île-de-Montréal du Québec, Montréal, Québec, Canada
4. Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec, Montréal, Québec, Canada
5. Social and Behavioural Health Sciences Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
6. School of Public Health and Social Policy, University of Victoria, Victoria, British Columbia, Canada

**Handling editor** Anna Maria Geretti

**Twitter** Nathan John Lachowsky @NJLachowsky

---

**Table 2** HCV seroprevalence ratios obtained by pooling three cross-sectional surveys of men who have sex with men conducted in Montréal, Québec (Canada) (2005, 2009, 2018)

| Covariates                                  | Univariable prevalence ratio (95% CI) | Multivariable prevalence ratio (95% CI) |
|---------------------------------------------|--------------------------------------|-----------------------------------------|
| History of IDU                              | 1.9 (0.9 to 4.1)                     | 2.2 (1.5 to 3.3)                        |
| Age <30                                      | 1.7 (1.7 to 2.5)                     | 1.7 (1.3 to 2.3)                        |
| Education level higher than high school     | 1.0 (0.7 to 1.4)                     | 1.4 (0.4 to 4.5)                        |
| Self-identified Indigenous ethnicity or family background | 1.1 (0.1 to 23.7)                     | 1.0 (0.7 to 1.3)                        |
| Reactive syphilis serology                  | 0.9 (0.4 to 1.9)                     | 0.7 (0.3 to 1.6)                        |
| First language other than French/English    | 1.0 (0.5 to 2.0)                     | 0.8 (0.6 to 1.2)                        |
| >5 male sexual partners (P6M)               | 1.0 (0.5 to 1.4)                     | 0.8 (0.6 to 1.2)                        |
| Group sex in the P6M                        | 0.7 (0.3 to 1.6)                     | 0.7 (0.3 to 1.6)                        |
| CAS with a man of serodiscordant/unknown HIV status (P6M) | 0.7 (0.3 to 1.6)                     | 0.7 (0.3 to 1.6)                        |

CAS, condomless anal sex; HCV, hepatitis C virus; IDU, injection drug use; P6M, past 6 months.
Epidemiology

Acknowledgements The principal investigators of Argus are Michel Alary, Chris Archibald, Joseph Cox, Louis-Robert Frigault, Marc-André Gaudry, Gilles Lambert, René Lavioe, Robert Remis, Paul Sandstrom, Cécile Tremblay, François Tremblay and Jon Vincelette. We would like to thank all men who agreed to participate in the Argus surveys, as well as the owners and managers of the establishments where the participants were recruited. We would also like to thank the gay community organisations in Montréal who supported this research. The principal investigators of Engage are Joseph Cox, Daniel Grace, Trevor Hart, Jody Jollimore, Nathan Lachowsky, Gilles Lambert and David Moore. We would like to thank all the Engage participants, the community engagement committee members and the affiliated community agencies.

Contributors CLD, JC, MK and MM-G conceived and designed the study. JC and GL were involved in the study design and data collection of the Argus 1 and 2 surveys. JC, GL, DG and NIL were involved in the study design and data collection of the Engage study. CLD administered and processed the different databases. CLD performed the statistical analyses with inputs from MK and MM-G. All authors contributed to results interpretation. CLD drafted the manuscript and all authors critically reviewed it for important intellectual content. All authors approved the final version.

Funding The Argus surveys were funded by the Institut national de santé publique du Québec and the Public Health Agency of Canada. Engagement is funded by the Canadian Institutes of Health Research, the Canadian Foundation for AIDS Research, and the Ontario HIV Treatment Network. CLD received a PhD trainee fellowship from the Canadian Network on Hepatitis C. The Canadian Network on Hepatitis C is funded by a joint initiative of theCanadian Institutes of Health Research (NHC-142832) and the Public Health Agency of Canada. CLD also received a doctoral training award from the Fonds de recherche du Québec – Santé. The authors thank the Réseau de recherche en santé des populations du Québec (RRSPQ) for its contribution to the financing of this publication.

Competing interests JC has received research grant funding from Gilead Sciences, Merck Canada and Viiv Healthcare. He also received travel support and honoraria for advisory work from Gilead Sciences, Merck Canada and Viiv Healthcare. MK reports grants for investigator-initiated studies from Viiv Healthcare, Merck and Gilead; research grants from Janssen; and personal fees from Viiv Healthcare, Bristol-Myers Squibb, Abbvie and Gilead, all outside the submitted work. MM-G reports grant funding from Gilead Sciences.

Patient consent for publication Not required.

Ethics approval The research ethics board of the Research Institute of the McGill University Health Centre approved all three surveys (Argus ethics committee number: A10-M66-04B; Engage ethics committee number: MP-CUSM-15-632).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Deidentified participant data used in this analysis are stored at the Direction régionale de santé publique Montréal and BCCTE. For information regarding these databases, and related access, please contact JC (joseph-constantin.ca; ORCID ID https://orcid.org/0000-0002-7041-1556), a principal investigator on both studies.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Nathan John Lachowsky http://orcid.org/0000-0002-6336-8780
Mathieu Maheu-Giroux http://orcid.org/0000-0002-8363-4388

REFERENCES

1 World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. World Health Organization, 2016.
2 Waheed Y, Siddiq M, Jamil Z, et al. Hepatitis elimination by 2030: progress and challenges. World J Gastroenterol 2018;24:6959-61.
3 The Canadian Network on Hepatitis C Blueprint Writing Committee and Working Groups. Blueprint to inform hepatitis C elimination efforts in Canada. Canadian Network on Hepatitis C, 2019.
4 Lazarus JV, Wiktor S, Columbo M, et al. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol 2017;67:655–6.
5 Lazarus JV, Safreed-Harmon K, Thurz MR, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis 2018;38:181–92.
6 Hagan H, Jordan AE, Neurer J, et al. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 2015;29:2335–45.
7 Ghisla V, Scherrer AU, Nicca D, et al. Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000-2016: a systematic review and meta-analysis. Infection 2017;45:309–21.
8 Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016;16:797–808.
9 Han R, Zhou J, François C, et al. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis 2019;19:655.
10 Newsum AM, van Rooijen MS, Kroone M, et al. Stable low hepatitis C virus antibody prevalence among HIV-negative men who have sex with men attending the sexually transmitted infection outpatient clinic in Amsterdam, 2007 to 2017. Sex Transm Infect 2018;45:813–7.
11 Falla AM, Hofstraat SJH, Dufell E, et al. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79.
12 Wong J, Moore D, Kanters S, et al. Seroprevalence of hepatitis C virus and correlates of seropositivity among men who have sex with men in Vancouver, Canada: a cross-sectional survey. Sex Transm Infect 2015;91:430–3.
13 Remis RS, Liu J, Huang MR, et al. Prevalence of sexually transmitted viral and bacterial infections in HIV-positive and HIV-negative men who have sex with men in Toronto. PLoS One 2016;11:e0158090.
14 Jin F, Matthews GV, Gullich AE. Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. Sex Health 2017;14:28–41.
15 McFaul K, Magliaoua A, Nizubua M, et al. Acute hepatitis C infection in HIV-negative men who have sex with men. J Viral Hepat 2015;22:535–8.
16 Volk JE, Marcus JL, Phengrasamy T, et al. Incident hepatitis C virus infections among users of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis 2015;60:1278–9.
17 Lachowsky N, Stephenson K, Cui Z, et al. Prevalence and factors of HCV infection among HIV-negative and HIV-positive MSM (abstract). Conference on retroviruses and opportunistic infections, 2016.
18 World Health Organization. Global hepatitis report. WHO, 2017.
19 Breskin A, Dobrnik A, Pathela P, et al. Factors associated with hepatitis C infection among HIV-infected men who have sex with men with no reported injection drug use in New York City, 2000–2010. Sex Transm Dis 2015;42:382–6.
20 Danti M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983–91.
21 Witt MD, Seaberg EC, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013;57:77–84.
22 Trubnikov M, Yan P, Njihia J, et al. Identifying and describing a cohort effect in the National database of reported cases of hepatitis C virus infection in Canada (1991–2010): an age-period-cohort analysis. CMAJ Open 2014;2:e281–7.
23 Greenaway C, Thu MA, K僚da LA, et al. The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: a systematic review and meta-analysis. PLoS One 2015;10:e0141715.
24 Schmidt AJ, Falcato L, Zahno B, et al. Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? BMC Public Health 2014;14:3.
25 Saxton PW, Hughes AJ, Robinson EM. Sexually transmitted diseases and hepatitis in a national sample of men who have sex with men in New Zealand. N Z Med J 2002;115:U106.
26 Chen Y-C, Wiiberg KJ, Hsieh Y-H, et al. Favorable socioeconomic status and recreational polydrug use are linked with sexual hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men. Open Forum Infect Dis 2016;3:ofw137.
27 Maxwell S, Shahnamesh M, Gafos M, Chemsex behaviours among men who have sex with men: a systematic review of the literature. Int J Drug Policy 2019;63:74–89.
28 Tomkins A, George R, Kliner M. Sexualised drug taking among men who have sex with men: a systematic review. Perspect Public Health 2019;139:23–33.
29 Alary M, Joly JR, Vincelette J, et al. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. Am J Public Health 2005;95:502–5.
30 Myers T, Allman D, Xu K, et al. The prevalence and correlates of hepatitis C virus (HCV) infection and HCV–HIV co-infection in a community sample of gay and bisexual men. Int J Infect Dis 2009;13:730–9.